DOR, PFS, and OS with ibrutinib. (A) DOR as assessed by the IRC. (B) PFS in the efficacy population (N = 60) as assessed by the IRC. (C) OS in the efficacy population (N = 60). The median PFS was 14.2 months (95% CI, 8.3 to NE), and the median OS has not been reached. The tick marks indicate patients with censored data.